AbbVie and Jacobio Pharmaceuticals have entered a global, strategic collaboration to develop and commercialize SHP2 inhibitors targeting a key node in cancer and immune cells. SHP2 is a key protein mediator of cellular signaling through RAS/MAP kinase pathway. Many tumors have genetic mutations, driving abnormal cancer cell growth which relies on SHP2 activity. SHP2 also plays a key role to control cytokine production and immune cell response. Therefore, inhibition of SHP2 is believed to hav...